Immunotherapy: Who Will Benefit?

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

From the death of author Paul Auster and musician Duane Eddy to King Charles’ visit to a cancer hospital, here’s what’s happening in the cancer space this week.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Alecensa was shown to reduce the risk of disease recurrence or death by 76% versus chemotherapy for patients with ALK-positive non-small cell lung cancer.

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.